Publicaciones en las que colabora con Raúl J. Andrade Bellido (34)

2022

  1. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2018

  1. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

  2. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

    Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948

  3. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

    Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300

  3. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2012

  1. Plasma Ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients

    Journal of Clinical Gastroenterology, Vol. 46, Núm. 4, pp. 328-333

2011

  1. La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74

2009

  1. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex

    Hepatology, Vol. 49, Núm. 6, pp. 2001-2009

  2. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

    Hepatology, Vol. 50, Núm. 6, pp. 1702-1708

2008

  1. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C

    Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727

  2. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C

    Hepatology, Vol. 47, Núm. 3, pp. 810-816

2007

  1. Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial

    Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95